KIR2DL3

Across TCGA pan-cancer cohorts, KIR2DL3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated KIR2DL3 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher KIR2DL3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KIR2DL3 expression acts as an unfavorable survival marker.

THYM, HNSC, and UCEC are the cancer types where KIR2DL3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	All	0.039	0.928	<.001	24	view →
HNSC	DFS	Median	All	0.178	0.712	<.001	24	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
PRAD	DFS	Median	All	0.068	0.774	<.001	6	view →
SKCM	DFS	Median	III,IV	0.087	0.647	.013	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

KIR2DL3–THYM (OS)

Open the THYM breakdown →